文章：

免疫检查点抑制剂联合放射疗法治疗晚期胰腺癌临床应用面临的挑战与机遇

Challenges and Opportunities for the Clinical Application of the Combination of Immune-Checkpoint Inhibitors and Radiation Therapy in the Treatment of Advanced Pancreatic Cancer

原文发布日期：11 February 2025

DOI: 10.3390/cancers17040606

类型: Article

开放获取: 是

英文摘要：

The treatment landscape of pancreatic ductal adenocarcinoma (PDAC) has seen slow progress, with immune-checkpoint inhibitors (ICIs) failing to replicate the success observed in other malignancies. The immune-suppressive tumor microenvironment (TME) in PDAC represents a significant barrier, limiting the activation of an effective antitumor immune response following ICI administration. Radiation therapy (RT), with its immunomodulatory effects, has emerged as a promising partner for ICIs. This review discusses the recent efforts evaluating the combination of ICIs and RT in advanced PDAC. While the combination therapy has demonstrated an acceptable safety profile, the reported clinical efficacy remains modest, particularly for patients with refractory metastatic PDAC. The ongoing phase III trial (JCOG1908E) will clarify whether the combination of ICI and RT improves overall survival in chemo-naïve patients with locally advanced PDAC.

摘要翻译： 

胰腺导管腺癌（PDAC）的治疗领域进展缓慢，免疫检查点抑制剂（ICIs）未能复制在其他恶性肿瘤中观察到的成功。PDAC中的免疫抑制性肿瘤微环境（TME）构成了一个重大障碍，限制了ICI给药后有效抗肿瘤免疫反应的激活。放射治疗（RT）凭借其免疫调节作用，已成为ICIs一个有前景的联合治疗伙伴。本综述讨论了近期评估ICIs与RT联合治疗晚期PDAC的研究进展。尽管联合治疗已显示出可接受的安全性，但报告的临床疗效仍然有限，特别是对于难治性转移性PDAC患者。正在进行的III期临床试验（JCOG1908E）将阐明ICI与RT联合治疗是否能改善初治局部晚期PDAC患者的总生存期。

原文链接：

Challenges and Opportunities for the Clinical Application of the Combination of Immune-Checkpoint Inhibitors and Radiation Therapy in the Treatment of Advanced Pancreatic Cancer